MedPath

The Wellbeing Program: A randomized controlled trial of internet based treatment of anxiety and depressio

Not Applicable
Completed
Conditions
Social phobia (an anxiety disorder)
Panic disorder (with or without agoraphobia) (both anxiety disorders)
Generalised anxiety disorder (an anxiety disorder)
Major depressive disorder (a depressive disorder)
Mental Health - Depression
Mental Health - Anxiety
Registration Number
ACTRN12610000247077
Lead Sponsor
Clinical Research Unit for Anxiety and Depression (CRUfAD), School of Psychiatry, University of New South Wales
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
80
Inclusion Criteria

Meet DSM-IV criteria for major depressive disorder, social phobia and/or panic disorder (with or without agoraphobia) and/or GAD
- Internet access + printer access
- Australian resident
- Males and females

Exclusion Criteria

- Current substance abuse/dependence
- Psychotic disorder
- Current or planned psychological treatment during study duration
- Change in medications during last 1 month or intended change during study duration
- Current use of benzodiazepines or beta-blockers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Anxiety is measured by the Generalised Anxiety Disorder 7 Item Scale (GAD-7)[Administered at pre-treatment, post-treatment, and at 3-months post-treatment];Social phobia is measured by the Social Phobia Scale (SPS)[Administered at pre-treatment, post-treatment, and at 3-months post-treatment];Social phobia is measured by the Social Interaction Anxiety Scale (SIAS)[Administered at pre-treatment, post-treatment, and at 3-months post-treatment]
Secondary Outcome Measures
NameTimeMethod
euroticism is measured by using the NEO-Five Factor Inventory (NEO-FFI) Neuroticism scale[Administered at pre-treatment, post-treatment, and at 3-months post-treatment];Disability is measured by the Sheehan Disability Scale (SDS)[Administered at pre-treatment, post-treatment, and at 3-months post-treatment];Psychological distress is measured by the Kessler 10-item scale (K-10)[Administered at pre-treatment, post-treatment, and at 3-months post-treatment];Panic disorder is measured by the Panic Disorder Severity Rating Scale - Self Report Version (PDSS-SR)[Administered at pre-treatment, post-treatment, and at 3-months post-treatment];Generalised anxiety disorder is measured by the Penn State Worry Questionnaire (PSWQ)[Administered at pre-treatment, post-treatment, and at 3-months post-treatment];Symptoms and severity of depression is measured by the Patient Health Questionnaire-9 (PHQ-9)[Administered at pre-treatment, post-treatment, and at 3-months post-treatment]
© Copyright 2025. All Rights Reserved by MedPath